

NOV 13 2007

Atty. Docket No.: 0944-UTL-GY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 10/541078

Inventor: Miranda

Filed: 6/29/05

Title: Water-soluble thioester and selenoester
compounds and methods for making and using the
same

Confirmation No.: 4061

TC/A.U.: 1654

Examiner: Heard

FACSIMILE TRANSMITTAL COVER SHEETCertificate of Transmission Under 37 C.F.R. 1.8

I hereby certify that the following listed correspondence in the above-referenced application is being transmitted by facsimile to the Commissioner for Patents, Alexandria, VA to telephone number (571) 273-8300 on this 12th of November 2007.


Suzi Mogavero

Document(s)

No. of
Pages

Power of Attorney to Prosecute Applications Before the USPTO

1

Statement Under 37 CFR 3.73(b) and additional papers if applicable

8

Fax Transmittal Cover Sheet

1

Total number of pages transmitted (including this page):

10

RECEIVED
CENTRAL FAX CENTER

NOV 13 2007

PTO/SB/80 (01-08)

Approved for use through 12/31/2008. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

☒ Practitioners associated with the Customer Number:

44638

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

☒ The address associated with Customer Number:

44638

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	Zip	
Country			
Telephone	Email		

Assignee Name and Address:

AMYLIN PHARMACEUTICALS, INC.


9360 TOWNE CENTRE DRIVE

SAN DIEGO, CA 92121

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date	11/12/07
Name	Lloyd A. Rowland	Telephone	858-552-2200
Title	VP, Governance and Compliance, and Corporate Secretary		

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

NOV 13 2007

0997-000-1

PTO/SB/86 (09-06)

Approved for use through 03/31/2007. OMB 0851-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Amylin Pharmaceuticals, Inc.Application No./Patent No.: 10/541078 Filed/Issue Date: 6/29/2005

Entitled:

AMYLIN PHARMACEUTICALS, INC.

corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

In the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 017042, Frame 0398, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

[Signature]
Signature
Lloyd A. Rowland

Date
858-552-2200

Printed or Typed Name

Telephone Number

VP, Governance & Compliance, and Corporate Secretary

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RightFax

1/20/06 3:22 PAGE 002/005 Fax Server

RECEIVED
CENTRAL FAX CENTER

NOV 13 2007

UNITED STATES PATENT AND TRADEMARK OFFICEUNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JANUARY 20, 2006

BTAS

500072426A~~*500072426A*~~MOLLY A HOLMAN, PH.D.
AMYLIN PHARMACEUTICALS, INC.
9360 TOWNE CENTRE DRIVE
SAN DIEGO, CA 92121UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT SERVICES DIVISION, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 01/20/2006

REEL/FRAME: 017042/0398
NUMBER OF PAGES: 5BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).
DOCKET NUMBER: 0944-GYASSIGNOR:
GRYPHON THERAPEUTICS, INC.

DOC DATE: 12/21/2005

ASSIGNEE:
AMYLIN PHARMACEUTICALS, INC.
9360 TOWNE CENTRE DRIVE
SAN DIEGO, CALIFORNIA 92121

SERIAL NUMBER: 60437285

FILING DATE: 12/30/2002

PATENT NUMBER:

ISSUE DATE:

TITLE: WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHODS FOR
MAKING AND USING THE SAME

11/12/2007 11:14 8585529098

PAGE 05

RightFax

1/20/08 3:22 PAGE 003/005 Fax server

017042/0398 PAGE 2

SERIAL NUMBER: 10541078

FILING DATE:

PATENT NUMBER:

ISSUE DATE:

TITLE: WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHODS FOR
MAKING AND USING THE SAME

ASSIGNMENT SERVICES BRANCH
PUBLIC RECORDS DIVISION

RightFax

1/20/06 3:22

PAGE 004/005

Fax Server

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

01/20/2006
500072426

RECEIVED
CENTRAL FAX CENTER
NOV 13 2007

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Gryphon Therapeutics, Inc.	12/21/2005
RECEIVING PARTY DATA	
Name:	Amylin Pharmaceuticals, Inc.
Street Address:	9360 Towne Centre Drive
City:	San Diego
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	60437285
Application Number:	10541078
CORRESPONDENCE DATA	
Fax Number:	(858)552-1936
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(858) 552-2200
Email:	ahalverson@amylin.com
Correspondent Name:	Molly A Holman, Ph.D.
Address Line 1:	Amylin Pharmaceuticals, Inc.
Address Line 2:	9360 Towne Centre Drive
Address Line 4:	San Diego, CALIFORNIA 92121
ATTORNEY DOCKET NUMBER:	0944-GY
NAME OF SUBMITTER:	Amanda J. Halverson
Total Attachments: 3 source=044 Assignment#page1.tif source=044 Assignment#page2.tif	

CH 580.00 60437285

RightFax

1/20/06 3:22

PAGE 005/005

Fax Server

source=044 Assignment#page3.tif

NOV 13 2007

Assignment of Applications and Patents to AMYLIN PHARMACEUTICALS, INC
Patent Family 044

ASSIGNMENT

WHEREAS, GRYPHON THERAPEUTICS, INC., of 35473 Dumbarton Ct., Newark, CA 94560 (c/o Rose Ryan), formerly of South San Francisco, California, United States of America, a Corporation of the State of California, the undersigned Assignor, hereby states it is the owner of each of the patent applications and patents identified herein and on the attached Exhibit 1 and inventions disclosed therein by virtue of obligations to assign to it by the original inventors or by virtue of Assignments to it by either the original inventors or by the previous owner Gryphon Sciences, of South San Francisco, California, United States of America;

WHEREAS, AMYLIN PHARMACEUTICALS, INC., of San Diego, California, United States of America, a Corporation of the State of Delaware, is desirous of acquiring the entire right, title and interest in and to said invention or inventions and any and all patents to be obtained therefor;

NOW, THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, the receipt of which is hereby acknowledged, GRYPHON THERAPEUTICS, INC. does hereby sell, assign and transfer to AMYLIN PHARMACEUTICALS, INC., ("Assignee") its successors and assigns, the entire right, title and interest in and to said application(s), patent(s) and/or invention(s), in any form or embodiment, whether or not listed in Exhibit 1; and in and to any and all applications filed in any country based thereon, whether or not listed in Exhibit 1, including the right to file applications in countries other than the country of priority filing under the provisions of any international convention; also the entire right, title and interest in and to any and all patents, including reissues and extensions thereof, obtained in any country upon said inventions, whether or not listed in Exhibit 1; and to any and all continuing applications, including divisional, continuation and continuation-in-part applications and substitute applications; to all prior applications disclosing said inventions to which said present application(s) or patents(s) claim priority, including any not listed in Exhibit 1; and to any other applications claiming the benefit of said prior applications, including any not listed in Exhibit 1.

Notwithstanding the foregoing paragraph, said application(s), patent(s), and/or invention(s) assigned and transferred hereby shall include only Assignor's rights to applications, patents and/or inventions relating directly to CPS Technology as defined in the Purchase Agreement between GRYPHON THERAPEUTICS, INC., and AMYLIN PHARMACEUTICALS, INC. dated November 28, 2005 (the "Purchase Agreement"), and shall not include Assignor's rights to applications, patents and/or inventions relating to patent families that are not listed in Schedule 1.1(a) to the Purchase Agreement.

GRYPHON THERAPEUTICS, INC. hereby authorizes and requests the issuing authority to issue any and all patents on said application or applications to AMYLIN

AND for the same consideration, GRYPHON THERAPEUTICS, INC. hereby covenants and agrees to and with AMYLIN PHARMACEUTICALS, INC., its successors, legal representatives and assigns, that GRYPHON THERAPEUTICS, INC. will, and, hereby

Assignment of Applications and Patents to AMYLIN PHARMACEUTICALS, INC
Patent Family 044

Page 2 of 3

grants to the Assignee the right to enforce the original inventors' obligations to assign their rights to **GRYPHON THERAPEUTICS, INC.** such that consistent with their obligations to assign to **GRYPHON THERAPEUTICS, INC.**, the original inventors will, whenever counsel of the said Assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent, or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said Assignee, its successors, legal representatives and assigns, but at the cost and expense of said Assignee, its successors, legal representatives and assigns.

IN TESTIMONY WHEREOF, **GRYPHON THERAPEUTICS, INC.** has hereto set its hands on the dates set after its signature.

Signature: F. Blobel Date: 12/21/05

Friedhelm Blobel

CEO and President



Gryphon Therapeutics, Inc.

State of California)

County of San Mateo

ss.

On this 21 day of December, 2005, before me, Sylvia Rogers, Notary Public, personally appeared Friedhelm Blobel, personally known to me or proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument and acknowledged that he/she executed the same as his/her free act and deed; in testimony whereof I have hereto set my hand and official seal on the day last above written.



Assignment of Applications and Patents to AMYLIN PHARMACEUTICALS, INC
 Patent Family 044

Page 3 of 3

Exhibit 1

Application or Patent No. (US and foreign)	Filing Date or Issuance Date	Country	Gryphon Docket Number	Issue Date	Patent	USPTO Recorded Prior Assignment to Gryphon Sciences (Reel/Frame)	USPTO Recorded Prior Assignment to Gryphon Therapeutics (Reel/Frame)
10/541,078	6/29/2005	UNITED STATES	044/00US				Reel: 015927 Frame: 0083
60/437,285	12/30/2002	UNITED STATES	044/00US PRV			Reel: 015273 Frame: 0948	
PCT/US03/41542	12/30/2003	WIPO	044/00WO				
03808599.9	12/30/2003	EUROPE	044/00EP				
2003303585	12/30/2003	AUSTRALIA					